Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes

Robert P. Brigance,Wei Meng,Aberra Fura,Thomas Harrity,Aiying Wang,Robert Zahler,Mark S. Kirby,Lawrence G. Hamann

DOI: https://doi.org/10.1016/j.bmcl.2010.06.063

IF: 2.94

2010-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of azolopyrimidines were prepared and evaluated in vitro and in vivo for DPP4 activity.

What problem does this paper attempt to address?

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Ning Li,Li-Jun Wang,Bo Jiang,Shu-Ju Guo,Xiang-Qian Li,Xue-Chun Chen,Jiao Luo,Chao Li,Yi Wang,Da-Yong Shi

DOI: https://doi.org/10.1016/j.bmcl.2018.05.022

IF: 2.94

2018-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of novel pyrimidinedione derivatives were designed and evaluated for in vitro dipeptidyl peptidase-4 (DPP-4) inhibitory activity and in vivo anti-hyperglycemic efficacy. Among them, the representative compounds 11, 15 and 16 showed excellent inhibitory activity of DPP-4 with IC50 values of 64.47 nM, 188.7 nM and 65.36 nM, respectively. Further studies revealed that compound 11 was potent in vivo hypoglycemic effect. The structure-activity relationships of these pyrimidinedione derivatives had been discussed, which would be useful for developing novel DPP-4 inhibitors as treating type 2 diabetes.
Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Yang Liu,Meimei Si,Li Tang,Shihao Shangguan,Haoshu Wu,Jia Li,Peng Wu,Xiaodong Ma,Tao Liu,Yongzhou Hu

DOI: https://doi.org/10.1016/j.bmc.2013.07.034

IF: 3.461

2013-01-01

Bioorganic & Medicinal Chemistry

Abstract:A series of novel benzyl-substituted (S)-phenylalanine derivatives were synthesized and evaluated for their dipeptidyl peptidase 4 (DPP-4) inhibitory activity and selectivity. It was found that most synthesized target compounds were potent DPP-4 inhibitors with IC50 values in 3.79-25.52 nM, which were significantly superior to that of the marketed drug sitagliptin. Furthermore, the 4-fluorobenzyl substituted phenylalanine derivative 6g not only displayed the potent DPP-4 inhibition with an IC50 value of 3.79 nM, but also showed better selectivity against DPP-4 over other related enzymes including DPP-7, DPP-8, and DPP-9. In an oral glucose tolerance test (OGTT) in normal Sprague Dawley rats, compound 6g reduced blood glucose excursion in a dose-dependent manner.
Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Y. Liu,Yucong Hu,T. Liu

DOI: https://doi.org/10.2174/092986712802002491

IF: 4.74

2012-01-01

Current Medicinal Chemistry

Abstract:Dipeptidyl peptidase 4 (DPP-4), a substrate-specific serine protease, has been validated as a promising drug target for the treatment of type 2 diabetes. DPP-4 inhibitors significantly lowered blood glucose levels in patients with type 2 diabetes without common body weight gain, hypoglycemia and gastrointestinal disturbance side effects. Therefore, DPP-4 inhibitors attracted more and more attention. In particular, non-peptidomimetic DPP-4 inhibitors have been a focus of research and development and made great progress in recent years, which resulted in the discovery of a wide variety of potent non-peptidomimetic DPP-4 inhibitors. Some of them, such as sitagliptin, alogliptin and linagliptin have already been used as marketed drugs, while others have been into clinical trials. Based on the core structural features of non-peptidomimetic DPP-4 inhibitors, seven types were classified in the article. For each type, we focused on the description of strategies for design and optimization, together with a discussion on concluded structure-activity relationships (SAR). In addition, the contribution of specific substituents to the inhibition of DPP-4 was summarized. Selectivity towards the inhibition of DPP-4 over dipeptidyl peptidase 8 (DPP-8) and dipeptidyl peptidase 9 (DPP-9) was also presented.
Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Jiang Wang,Ying Feng,Xun Ji,Guanghui Deng,Ying Leng,Hong Liu

DOI: https://doi.org/10.1016/j.bmc.2013.09.048

IF: 3.461

2013-01-01

Bioorganic & Medicinal Chemistry

Abstract:A novel series of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives was designed, synthesized, and found to act as dipeptidyl peptidase-4 (DPP-4) inhibitors. From this series of compounds, compound 17a was identified as an efficacious, safe, and selective inhibitor of DPP-4. In vivo studies in ICR and KKAy mice showed that administration of this compound resulted in decreased blood glucose in these mice after an oral glucose challenge. Compound 17a showed high DPP-4 inhibitory activity (IC(50)=0.017 μM), moderate selectivity against DPP-4 (selective ratio: DPP-8/DPP-4=1324; DPP-9/DPP-4=1164), and good efficacy in oral glucose tolerance tests in ICR and KKAy mice. These in vivo anti-diabetic properties and its desirable pharmacokinetic profile in Sprague-Dawley rats demonstrate that compound 17a is a promising candidate for development as an anti-diabetic agent.
Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Jing Wu,Yiding Chen,Xiaoli Shi,Wei Gu

DOI: https://doi.org/10.1016/s1007-4376(09)60061-7

2009-01-01

Abstract:The enzyme, dipeptidyl peptidase IV(DPP IV), is a novel target for the treatment of type 2 diabetes. Dipeptidyl peptidase IV inhibition improves the impaired insulin secretion and decrease postprandial concentrations of glucagon by enhancing the incretin hormone levels lucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide(GIP). Recently, DPP IV inhibitors have attracted more and more attention, several of which have entered pre-clinical and clinical trials, and one has received approval for use as an anti-diabetic agent. Among the DPP IV inhibitors, two leading agents(sitagliptin and vildagliptin) have been shown to be effective in reducing glycosylated hemoglobin(HbA1c) and fasting plasma glucose(FPG) in patients with type 2 diabetes. This review summarizes the evidence supporting DPP IV inhibitors as potential antidiabetic agents.
Synthesis and Biological Evaluation of Azobicyclo[3.3.0] Octane Derivatives As Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes

Tang Peng Cho,Yang Fang Long,Lin Zhi Gang,Wang Yang,Lu He Jun,Shen Guang Yuan,Fu Jian Hong,Wang Lin,Guan Dong Liang,Zhang Lei,Jing,Gong Ai Shen,She Gao Hong,Wang Dan,Feng Ying,Yan Pang Ke,Leng Ying,Feng Jun,Mong Xian Tai

DOI: https://doi.org/10.1016/j.bmcl.2010.04.120

IF: 2.94

2010-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of novel bicyclo[3.3.0]octane derivatives have been synthesized and found to be dipeptidyl peptidase 4 (DPP-4) inhibitors. Compounds 10a and 10b demonstrate good efficacies in oral glucose tolerance tests.
Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.

Wei Meng,Robert P. Brigance,Hannguang J. Chao,Aberra Fura,Thomas Harrity,Jovita Marcinkeviciene,Stephen P. O’Connor,James K. Tamura,Dianlin Xie,Yaqun Zhang,Herbert E. Klei,Kevin Kish,Carolyn A. Weigelt,Huji Turdi,Aiying Wang,Robert Zahler,Mark S. Kirby,Lawrence G. Hamann

DOI: https://doi.org/10.1021/jm100634a

IF: 8.039

2010-01-01

Journal of Medicinal Chemistry

Abstract:Continued structure activity relationship (SA R) exploration within our previously disclosed azolopyrimidine containing dipeptidyl peptidase-4 (DPP4) inhibitors led us to focus on an imidazolopyrimidine series in particular. Further study revealed that by replacing the aryl substitution on the imidazole ring with a more polar carboxylic ester or amide, these compounds displayed not only increased DPP4 binding activity but also significantly reduced human ether-a-go-go related gene (hERG) and sodium channel inhibitory activities. Additional incremental adjustment of polarity led to permeable molecules which exhibited favorable pharmacokinetic (PK) profiles in preclinical animal species. The active site binding mode of these compounds was determined by X-ray crystallography as exemplified by amide 24c. A subsequent lead molecule from this series, (+)-6-(aminomethyl)-5-(2,4-dichlorophenyl)-N-(1-ethyl-1H-pyrazol-5-yl)-7-methylimidazo[1,2-c]pyrimidine-2-carboxamide (24s), emerged as a potent, selective DPP4 inhibitor that displayed excellent PK profiles and in vivo efficacy in ob/ob mice.
Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Yang Liu,Chaoyi Jiang,Haoshu Wu,Peng Wu,Meimei Si,Yongzhou Hu,Tao Liu

DOI: https://doi.org/10.2174/1573406411309070007

2013-01-01

Medicinal Chemistry

Abstract:A series of novel imidazolone derivatives were designed and synthesized via a rational drug design strategy. These compounds were obtained from 3-substituted imidazolidine-2,4-dione through alkylation, formylation, dehydration, and amination. The structures were characterized by (1)H NMR, (13)C NMR, and MS. All target compounds were screened for their DPP-4 inhibitory activity in vitro. The results revealed that some imidazolone derivatives showed potent DPP-4 inhibition. Compound 5b had an IC50 value of 2.21 µM inhibitory activity against DPP-4. As a promising lead compound, compound 5b with DPP-4 binding mode was further studied by docking analysis. The expected interaction mode was obtained.
Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors

Na Luo,Xiaoyu Fang,Mingbo Su,Xinwen Zhang,Dan Li,Honglin Li,Shiliang Li,Zhenjiang Zhao

DOI: https://doi.org/10.1002/cjoc.202000342

IF: 5.56

2020-12-23

Chinese Journal of Chemistry

Abstract:Dipeptidyl Peptidase 4 (DPP‐4) is a clinically validated target for the treatment of type 2 diabetes mellitus (T2DM). To discover novel and potent DPP‐4 inhibitors, three series of compounds were designed and synthesized in this study based on our previously identified novel scaffold of 2‐phenyl‐3,4‐dihydro‐2H‐benzo[f]chromen‐3‐amine. Among the designed compounds, 41d‐1 was the most potent one with an IC50 value of 16.00 nM. Besides, 41d‐1 (5 mg/kg) displayed a moderate glucose tolerance capability in ICR mice. Structure‐activity‐relationship (SAR) studies were discussed in detail, which is constructive for our further optimization.This article is protected by copyright. All rights reserved.

chemistry, multidisciplinary
Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Yang Liu,Yizhe Wu,Haoshu Wu,Li Tang,Peng Wu,Tao Liu,Yongzhou Hu

DOI: https://doi.org/10.1111/cbdd.12139

2013-01-01

Chemical Biology & Drug Design

Abstract:A novel series of (S)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety were designed and synthesized through a rational drug design strategy. Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors; among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247m. In addition, molecular docking analysis of the representative compounds 11h, 11k, and 15a were performed, which not only revealed the impact of binding modes on DPP-4 inhibitory activity but also provided additional methodological values for design and optimization.
Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4

Yan Zhu,Xiangguo Meng,Zhengyan Cai,Qun Hao,Weicheng Zhou

DOI: https://doi.org/10.1007/s10593-017-2062-4

2017-03-01

Chemistry of Heterocyclic Compounds

Abstract:A novel series of pyridine-based derivatives was synthesized and evaluated for their inhibitory activity against dipeptidyl peptidase-4 (DPP4). 5-Aminomethyl-6-(2,4-dichlorophenyl)-4-[(1H-1,2,4-triazol-1-yl)methyl]pyridine-2-carboxylic acid was identified as a potent (IC50 0.57 nM) and selective DPP4 inhibitor (DPP8/DPP4 = 238). A docking study of this compound revealed a hydrogen-bonding interaction with the Arg125 residue of the enzyme providing a potential target residue for further structural optimization.

chemistry, organic
Synthesis of β-Amino Carbonyl 6-(Aminomethyl)- and 6-(Hydroxymethyl)pyrazolopyrimidines for DPP-4 Inhibition Study

Cheng-Yen Chung,Ching-Chun Tseng,Sin-Min Li,Wei-Zheng Zeng,Yu-Ching Lin,Yu-Pei Hu,Wen-Ping Jiang,Guan-Jhong Huang,Fung Fuh Wong,Henry J. Tsai

DOI: https://doi.org/10.2174/0929867329666220614094305

IF: 4.74

2022-06-14

Current Medicinal Chemistry

Abstract:Background: Type-2 diabetes is a chronic progressive metabolic disease resulting in severe vascular complications and mortality risk. Recently, DPP-4 inhibitors are conceived as a favorable class of agents for the treatment of type 2 diabetes due to the minimal side effects. Methods: Sitagliptin is the first medicine approved for DPP-4 inhibitor. Its structure involved three fragments: 2,4,5-triflorophenyl fragment pharmacophore, enantiomerically β-amino carbonyl linker, and tetrahydrotriazolopyridine. Herein, we are drawn to the possibility of substituting tetrahydrotriazolopyridine motif present in Sitagliptin with a series of new fused pyrazolopyrimidine bicyclic fragment to investigate potency and safety. Results: Two series of fused 6-(aminomethyl)pyrazolopyrimidine and 6-(hydroxymethyl)pyrazolopyrimidine derivatives containing β-amino ester or amide as linkers were successfully designed for the new DPP-4 inhibitors. Most fused 6-methylpyrazolopyrimidines were evaluated against DPP-4 inhibition and selectivity capacity. Based on research study, β-amino carbonyl fused 6-(hydroxymethyl)pyrazolopyrimidine possesses the significant DPP-4 inhibition (IC50 ≤ 59.8 nM) and presents similar with Sitagliptin (IC50 = 28 nM). Particularly, they had satisfactory selectivity over DPP-8 and DPP-9, except for QPP. Conclusion: β-Amino esters and amides fused 6-(hydroxymethyl)pyrazolopyrimidine were developed as the new DPP-4 inhibitors. Those compounds with a methyl group or hydrogen in N-1 position and methyl substituted group in C-3 of pyrazolopyrimidine moiety showed better potent DPP-4 inhibition (IC50 = 21.4–59.8 nM). Furthermore, they had satisfactory selectivity over DPP-8 and DPP-9 Finally, the docking results revealed that compound 9n was stabilized at DPP-4 active site and would be a potential lead drug.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

Chao Lin,Ying Kong,Furong Wang,Rong Rong,Xiangping Li,Rensong Xiao,Ziqi Wu,Qiuyan Zhang,Lin Wang

DOI: https://doi.org/10.1016/j.bioorg.2022.105767

IF: 5.307

2022-06-01

Bioorganic Chemistry

Abstract:Type 2 diabetes mellitus (T2DM) is one of the most popular chronic diseases around the whole world. To improve the compliance of patients, long-acting antidiabetic drugs needed to be developed. Dipeptidyl peptidase-4 (DPP-4) inhibitors are becoming increasingly important in the T2DM treatment due to the favorable properties. In the present study, a series of new substituted dihydropyrido [4',3':3,4] pyrazolo [1,5-a] pyrimidin-9(10H)-yl)-2-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-amine were designed and synthesized as potent DPP-4 inhibitors. All compounds were characterized by 1H NMR, 13C NMR and HRMS and were evaluated in vitro. The inhibitory activity ranged from 0.43 to 12.70 μM while the inhibitory activity of positive control (omarigliptin) was 3.63 μM on DPP-4 in Caco-2 cells. Then pharmacokinetic studies were carried out in rats and compound 6c was finally selected for the further study because of its better pharmacokinetic profile. Additionally, preclinical pharmacological study of compound 6c exhibited extraordinary efficacy in vivo and good safety profile. In conclusion, compound 6c was considered as a promising DPP-4 inhibitor, which could be taken once a week or once every two weeks for the treatment of T2DM. More comprehensive researches will be carried out in the future for the further development of compound 6c.

biochemistry & molecular biology,chemistry, organic
Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Deyan Wu,Fangfang Jin,Weiqiang Lu,Jin Zhu,Cui Li,Wei Wang,Yun Tang,Hualiang Jiang,Jin Huang,Guixia Liu,Jian Li

DOI: https://doi.org/10.1111/j.1747-0285.2012.01365.x

2012-01-01

Chemical Biology & Drug Design

Abstract:Type 2 diabetes mellitus (T2DM) is a metabolic disease and a major challenge to healthcare systems around the world. Dipeptidyl peptidase IV (DPP-4), a serine protease, has been rapidly emerging as an effective therapeutic target for the treatment for T2DM. In this study, a series of novel DPP-4 inhibitors, featuring the pyrazole-3-carbohydrazone scaffold, have been discovered using an integrated approach of structure-based virtual screening, chemical synthesis, and bioassay. Virtual screening of SPECS Database, followed by enzymatic activity assay, resulted in five micromolar or low-to-mid-micromolar inhibitory level compounds (15) with different scaffold. Compound 1 was selected for the further structure modifications in considering inhibitory activity, structural variability, and synthetic accessibility. Seventeen new compounds were synthesized and tested with biological assays. Nine compounds (6e, 6g, 6kl, and 7ae) were found to show inhibitory effects against DPP-4. Molecular docking models give rational explanation about structureactivity relationships. Based on eight DPP-4 inhibitors (15, 6e, 6k, and 7d), the best pharmacophore model hypo1 was obtained, consisting of one hydrogen bond donor (HBD), one hydrogen bond acceptor (HBA), and two hydrophobic (HY) features. Both docking models and pharmacophore mapping results are in agreement with pharmacological results. The present studies give some guiding information for further structural optimization and are helpful for future DPP-4 inhibitors design.
Synthesis, SAR, and Atropisomerism of Imidazolopyrimidine DPP4 Inhibitors

Stephen P. O'Connor,Ying Wang,Ligaya M. Simpkins,Robert P. Brigance,Wei Meng,Aiying Wang,Mark S. Kirby,Carolyn A. Weigelt,Lawrence G. Hamann

DOI: https://doi.org/10.1016/j.bmcl.2010.08.090

IF: 2.94

2010-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:The synthesis and SAR of aminomethyl-substituted imidazolopyrimidine DPP4 inhibitors bearing varied pendant aryl groups is described. Compound 1, which exists as a separable mixture of non-interconvertible atropisomers was used as the starting point for investigation. The effects of substituent pattern and type as well as stereochemical effects on inhibitor potency are discussed.
Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

Xun Ji,Chunmei Xia,Jiang Wang,Mingbo Su,Lei Zhang,Tiancheng Dong,Zeng Li,Xia Wan,Jingya Li,Jia Li,Linxiang Zhao,Zhaobing Gao,Hualiang Jiang,Hong Liu

DOI: https://doi.org/10.1016/j.ejmech.2014.08.059

IF: 7.088

2014-01-01

European Journal of Medicinal Chemistry

Abstract:Based on the previous work in our group and the principle of computer-aided drug design, a series of novel β-amino pyrrole-2-carbonitrile derivatives was designed and synthesized. Compounds 8l and 9l were efficacious and selective DPP4 inhibitors resulting in decreased blood glucose in vivo. Compound 8l had moderate DPP4 inhibitory activity (IC50 = 0.05 μM) and good oral bioavailability (F = 53.2%). Compound 9l showed excellent DPP4 inhibitory activity (IC50 = 0.01 μM), good selectivity (selective ratio: DPP8/DPP4 = 898.00; DPP9/DPP4 = 566.00) against related peptidases, and good efficacy in an oral glucose tolerance tests in ICR mice and moderate PK profiles (F = 22.8%, t1/2 = 2.74 h). Moreover, compound 9l did not block hERG channel and exhibited no inhibition of liver metabolic enzymes such as CYP2C9.
Discovery of novel heterocyclic derivatives containing oxadiazolone or pyrimidinone cores as DPP‐4 inhibitors

Sidney Gustavo Diniz Feitosa,Ilária Martina Silva Lins,Larissa Gonçalves Maciel,Janaína Versiani dos Anjos

DOI: https://doi.org/10.1002/jhet.4811

2024-03-25

Journal of Heterocyclic Chemistry

Abstract:Our investigation introduces a novel class of DPP‐4 inhibitors and contributes to the ongoing efforts to develop new type 2 diabetes drugs. Type 2 diabetes is a chronic disease characterized by insulin resistance and alterations in incretin secretion, such as the glucagon‐like peptide‐1 (GLP‐1) hormone. GLP‐1 plays a crucial role in signaling insulin production in the pancreas, with its activity regulated by the dipeptidyl peptidase 4 (DPP‐4) enzyme. DPP‐4 presents an intriguing strategy for controlling type 2 diabetes. This study focuses on synthesizing 22 novel oxadiazolone and pyrimidinone derivatives, in vitro DPP‐4 inhibition, and elucidating binding modes through molecular docking simulations. Nine compounds showed promising inhibitory activity, with IC50 values ranging from 0.3 to 1.86 mM. Molecular docking simulations revealed interactions between these compounds and critical residues in the enzyme's active site, such as Arg125, Glu206, Ser630, and His740. This investigation introduces a new class of DPP‐4 inhibitors, providing insights into the design of more potent molecules as potential candidates for combating type 2 diabetes. The findings contribute to developing innovative therapeutics for managing this prevalent metabolic disorder.

chemistry, organic
Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents

Ladan Baziar,Leila Emami,Zahra Rezaei,Aida Solhjoo,Amirhossein Sakhteman,Soghra Khabnadideh

DOI: https://doi.org/10.1038/s41598-024-77481-9

IF: 4.6

2024-11-04

Scientific Reports

Abstract:A novel series of 4-aminopiperidin-3,4-dihyroquinazoline-2-uracil derivatives (9a-9 L) were logically designed and synthesized as potent DPP4 inhibitors as antidiabetic agents. Chemical structure of all new compounds were confirmed by different spectroscopic methods. The designed compounds were evaluated using a MAK 203 kit as DPP4 inhibitors in comparison with Sitagliptin. The biological evaluation revealed that compound 9i bearing chloro substitution on phenyl moiety of 6-bromo quinazoline ring had promising inhibitory activity with IC 50 = 9.25 ± 0.57 μM. The toxicity test of all compounds confirmed safety profile of them. Kinetic studies showed that compound 9i exhibited a competitive-type inhibition with a K i value of 12.01 μM. Computational approach supported the rationality of our design strategy, as 9i represented appropriate binding interactions with the active sites of DPP4 target. MD simulation outputs validated the stability of ligand 9i at DPP4 active site. Also, Density functional theory (DFT) including HOMO-LUMO energies, ESP map, thermochemical parameters, and theoretical IR spectrum was employed to study the reactivity descriptors of 9i and 9a as the most and least potent compounds respectively. Based on the DFT study, compound 9i was softer and, as a result, more reactive than 9a. Taken together, our results showed the potential of 4-aminopiperidin-3,4-dihyroquinazoline-2-uracil derivatives as promising candidates for developing some novel DPP4 inhibitors for managing of type 2 diabetes.

multidisciplinary sciences
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.

Wei Wang,Pratik Devasthale,Aiying Wang,Tom Harrity,Don Egan,Nathan Morgan,Michael Cap,Aberra Fura,Herbert E Klei,Kevin Kish,Carolyn Weigelt,Lucy Sun,Paul Levesque,Yi-Xin Li,Robert Zahler,Mark S Kirby,Lawrence G Hamann

DOI: https://doi.org/10.1016/j.bmcl.2011.09.074

IF: 2.94

2011-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Design, synthesis, and SAR of 7-oxopyrrolopyridine-derived DPP4 inhibitors are described. The preferred stereochemistry of these atropisomeric biaryl analogs has been identified as Sa. Compound (+)-3t, with a Ki against DPP4, DPP8, and DPP9 of 0.37nM, 2.2, and 5.7μM, respectively, showed a significant improvement in insulin response after single doses of 3 and 10μmol/kg in ob/ob mice.
Discovery and Preclinical Profile of Saxagliptin (BMS-477118): a Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

DJ Augeri,JA Robl,DA Betebenner,DR Magnin,A Khanna,JG Robertson,AY Wang,LM Simpkins,P Taunk,Q Huang,SP Han,B Abboa-Offei,M Cap,L Xin,L Tao,E Tozzo,GE Welzel,DM Egan,J Marcinkeviciene,SY Chang,SA Biller,MS Kirby,RA Parker,LG Hamann

DOI: https://doi.org/10.1021/jm050261p

IF: 8.039

2005-01-01

Journal of Medicinal Chemistry

Abstract:Efforts to further elucidate structure-activity relationships (SAR) within our previously disclosed series of beta-quaternary amino acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the beta-position of alpha-cycloalkyl-substituted glycines. Despite poor systemic exposure, vinyl-substituted compounds showed extended duration of action in acute rat ex vivo plasma DPP-IV inhibition models. Oxygenated putative metabolites were prepared and were shown to exhibit the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zucker(fa/fa) rats. Extension of this approach to adamantylglycine-derived inhibitors led to the discovery of highly potent inhibitors, including hydroxyadamantyl compound BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor, which is currently undergoing clinical trials for treatment of type 2 diabetes.

Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Synthesis and Biological Evaluation of Azobicyclo[3.3.0] Octane Derivatives As Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes

Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4

Synthesis of β-Amino Carbonyl 6-(Aminomethyl)- and 6-(Hydroxymethyl)pyrazolopyrimidines for DPP-4 Inhibition Study

Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Synthesis, SAR, and Atropisomerism of Imidazolopyrimidine DPP4 Inhibitors

Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

Discovery of novel heterocyclic derivatives containing oxadiazolone or pyrimidinone cores as DPP‐4 inhibitors

Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents

7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.

Discovery and Preclinical Profile of Saxagliptin (BMS-477118): a Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.